Latest news with #MarketAnalysis
Yahoo
09-06-2025
- Business
- Yahoo
Bladder Cancer Drug Market Forecast and Analysis Report 2025: Focus on US, France, Germany, Italy, Spain, UK, Japan, and China - Epidemiology, Pipeline Therapies, 10 Year Forecasts
Explore the comprehensive "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report, covering the 8 major markets (US, France, Germany, Italy, Spain, UK, Japan, China). Gain insights into disease epidemiology, 10-year patient-based forecasts, and market trends, as well as late-stage pipeline therapies set to drive market growth. Dublin, June 09, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer: Eight-Market Drug Forecast and Market Analysis" report has been added to Highlights Report deliverables include a Pdf report and Excel-based forecast model Forecasts includes the 8MM Forecasts covers from 2021-2031 The analyst valued the bladder cancer market in the 8MM at $2.39 billion and expects the market to increase to $2.89 billion by 2031 Incyte, GSK and CTI BioPharma are expected to take market-leading position in 2031 A moderate level of unmet need will remain for most bladder cancer patient populations during the forecast period The late-stage pipeline in bladder cancer is robust and is likely to provide significant clinical benefit to many bladder cancer patient populations, with fierce competition expected This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the 8MM for marketed and late-stage pipeline therapies, with a launch date assessment by market for bladder cancer. These sales forecasts leverage data on pharmaceutical sales and drug availability from the analyst's World Markets Healthcare (WMH) and POLI Price Intelligence being a rare blood cancer, MF is a blockbuster market and is expected to grow from sales of $2.39 billion in 2021 to $2.89 billion in 2031, at a compound annual growth rate (CAGR) of 1.9%. Peak-year sales are set to be reached in 2027, driven by the approvals of several promising late-stage pipeline agents and the continued clinical dominance of Jakafi/Jakavi (ruxolitinib). In 2028, Jakafi/Jakavi is set to come off-patent in the US, which will greatly decrease its total market sales. However, the loss of total market sales will be somewhat recuperated in 2028 and beyond by the additional growth in market value of other pipeline Janus kinase (JAK) inhibitors and targeted therapies, with sales of these agents being driven by ameliorating critical unmet needs within the MF treatment markets across the 8MM will experience growth driven by common drivers: Approvals of late-stage pipeline agents, including novel JAK inhibitors and targeted therapies, which will partially meet critical unmet clinical needs Decreased reliance on generic immunomodulatory agents, androgens, and erythropoietin-stimulating agents Increased utilization of novel combination regimens with premium-priced agents Common barriers to market growth experienced across the 8MM primarily include a series of patent expiries: Patent expiry of Jakafi/Jakavi Patent expiry of Vonjo (pacritinib) Patent expiry of Inrebic (fedratinib) Key Highlights This report covers the eight major markets (8MM: US, France, Germany, Italy, Spain, the UK, Japan and China). The report provides an overview of the current treatment options, pipeline products in development, as well as current and future R&D trends. Key topics covered include a strategic competitive assessment of current and future drugs, unmet needs, KOL insights, and implications for the severe asthma market. The base year of the sales forecast model is 2023, and the forecast period is 2023-2033. Scope Overview of bladder cancer, including epidemiology, symptoms, diagnosis, and disease management. Annualized bladder cancer therapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2023 to 2033. Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the bladder cancer therapeutics market. Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for bladder cancer treatment. The most promising candidates in Phase III and Phase IIb development are profiled. Analysis of the current and future market competition in the global bladder cancer therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications Reasons to Buy Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Develop business strategies by understanding the trends shaping and driving the global bladder cancer therapeutics market. Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global bladder cancer therapeutics market in the future. Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships Key Topics Covered: Abbreviations Related Reports Executive Summary Disease Overview Overview of Bladder Cancer Bladder Cancer Market Strength, Weakness, Opportunity, and Threat Analysis Epidemiology Diagnosed Incident Cases Both Sexes Age-Specific Diagnosed Incident Cases Sex-Specific Diagnosed Incident Cases Diagnosed Incident Cases by Type, Sex, Age Diagnosed Incident Cases by Stage at Diagnosis Diagnosed Incident Cases by Tumor Stage at Diagnosis Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Diagnosed Incident Cases of Stage of Bladder Cancer by Broad Classification Diagnosed Incident Cases of Stage of NMIBC by Risk Group Diagnosed Incident Cases of Bladder Cancer by Mutations and Biomarkers Five-Year Diagnosed Prevalent Cases of Bladder Cancer Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Tumor Stage Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Broad Classification Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Relapse or Recurrence Five-Year Diagnosed Prevalent Cases of Bladder Cancer by Treatment Disease Management Treatment Guidelines Treatment Paradigm - First-Line Therapy in Non-Muscle Invasive Bladder Cancer Treatment Paradigm - First-Line Therapy in Muscle Invasive Bladder Cancer Treatment Paradigm - Locally Advanced/Metastatic Bladder Cancer KOL Insight on the Bladder Cancer Treatment Algorithm Unmet Needs and Opportunities Unmet Needs in Bladder Cancer Competitive Landscape Assessment Pipeline Drugs Overview Competitive Landscape Methodology Competitive Assessment - Intravesical Delivered Therapies for NMIBC Competitive Assessment - Gene Therapies for NMIBC Competitive Assessment - Antibody-Drug Conjugates Market Outlook Bladder Cancer Market Forecast Bladder Cancer Market Forecast by Class Bladder Cancer Market Drivers and Barriers Appendix Primary Research: KOL Information Sources Used and Not Used to Forecast Diagnosed Incident Cases Sources Used to Forecast Diagnosed Incident Cases by Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases by Tumor Stage at Diagnosis Sources Used to Forecast Diagnosed Incident Cases of Stage Ta Bladder Cancer by Grade Sources Used to Forecast Diagnosed Incident and Five-Year Diagnosed Prevalent Cases by Broad Classification Sources Used to Forecast Diagnosed Incident Cases of NMIBC by Risk Group Sources Used to Forecast Diagnosed Incident Cases by Mutations and Biomarkers Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Relapse or Recurrence Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases by Treatment Sources and Methodology Epidemiological Forecast Insight Strengths and Limitations A selection of companies mentioned in this report includes, but is not limited to: AstraZeneca Merck Bristol-Myers Squibb Gilead Sciences LLC Roche Pfizer Immunomedics Inc Astellas Pharma Co Ltd Johnson & Johnson Daiichi Sankyo Co Ltd Ferring Pharmaceuticals Ltd ImmunityBio Inc BeiGene Ltd Bicycle Therapeutics Inc CG Oncology Inc Shanghai Miracogen Inc Fidia farmaceutici SpA Therlase Inc enGene Holdings Inc UroGen Pharma Inc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
![Savvylong [2X] Tsla ETF](/_next/image?url=https%3A%2F%2Fwww.theglobeandmail.com%2Fpf%2Fresources%2Fassets%2Fmeta%2Ftwitter-summary-240x240.png%3Fd%3D707&w=3840&q=100)
![Savvylong [2X] Tsla ETF](/_next/image?url=https%3A%2F%2Fstatic-mobile-files.s3.eu-central-1.amazonaws.com%2Fglobe-and-mail.png&w=48&q=75){kind=small}
Globe and Mail
05-06-2025
- Business
- Globe and Mail
Savvylong [2X] Tsla ETF
Day Low 12.76 Day High 17.96 Open: 17.96 Price movement based on the high, low and last over the given period.
Globe and Mail
02-06-2025
- Business
- Globe and Mail
Gold Is Bullish, But Be Aware Of Deeper Intraday Pullback; Elliott Wave Intraday Analysis
Good morning traders! USDollar Index - DXY remains under intraday bearish pressure at the start of the month and week, so we are definitely still bearish and expect more weakness, but it's early Monday and we may not see straight lines, thus still be aware of bigger or more complex intraday pullback before a bearish continuation. DXY could actually still be trading in subwave (b) and it can still see higher intraday resistance for subwave (c) of "ii", which can fill the GAP from May 18 before real bears show up. However, of course, if DXY breaks below 98 area decisively, then more weakness can be seen within wave "iii" of 5, unless it goes sideways for a higher degree bearish triangle in wave 4. Gold is coming nicely higher for wave subwave »c« of a projected three-wave abc corrective recovery in wave B and it's now testing key resistance, from where we may see another sell-off for a wave C of a higher degree wave (2), especially if we consider a new open GAP at 3925 level and then prevoius one at 3200 area, which can act as a strong support. However, if gold breaks straight above 3367 level decisively, then higher degree wave (3) can be already in full progress.
Globe and Mail
25-05-2025
- Business
- Globe and Mail
Gold Analysis & Targets 5/25/25
Gold Futures Analysis The chart is key to this update. (GCM25) From last week, The failure to make a new high in the area of a 78.6% retracement (also a major Gann square) hit the first target of 78.6% the other way at 3268.00 per the ONE44 78.6% rule and we will now see if it is also the end of the Bull run for now. It traded below the short term target of 3164.40, but never closed below it, this was 38.2% back to the 11/14/24 low and a major Gann square. This will be the key level for next week. Use 3164.40 as the swing point for the week. Above it, being a 38.2% retracement, holding it can send this market to a new high per the ONE44 38.2% rule. The longer term target is 78.6% back to the 4/22/25 high at 3430.00. The short term target area is the 3356.70 major Gann square and 61.8% back to the same high at 3366.00. Any rally that can't get above 38.2% of the same move at 3273.00 is very negative and a new low can quickly follow. 5/25/25 After spiking below 38.2% at 3164.00 (also a major Gann square), but never closing below it, it has rallied $200 and now hit the short term target area of the 3356.70 major Gann square and 61.8% back to the 4/22/25 high at 3366.00, this will be the key level for next week. We will use the ONE44 61.8% rule to get the short term downside target. Use 3366.00 as the swing point for the week. Above it, The low on 5/15/25 held 38.2% at 3164.40 and following the ONE44 38.2% rule we are still looking for a new ATH from it for the long term target. The short term target area is 78.6% of the same move at 3430.00 and the 3446.00 major Gann square. Below it, a setback from a 61.8% retracement can send it 61.8% the other way at 3220.00 per the ONE44 61.8% rule, this is the short term target. The long term target area is 78.6% of the same move at 3178.00 and the 3164.40 major Gann square. Any setback that holds 38.2% at 3276.00 keeps the short term trend extremely positive and a new high can quickly follow. We have done 47 videos on how to use the Fibonacci retracements with the ONE44 rules and guidelines. These Videos are worth watching even if it is not in the market you are trading, as the ONE44 rules and guidelines are the same for every market. You will also see why we believe the Fibonacci retracements are the underlying structure of ALL markets. Here is the latest. Sign up for free updates for Gold, Crude Oil, SP 500 and Bitcoin here. ONE44 Analytics where the analysis is concise and to the point Our goal is to not only give you actionable information, but to help you understand why we think this is happening based on pure price analysis with Fibonacci retracements, that we believe are the underlying structure of all markets and Gann squares. If you like this type of analysis and trade the Grain/Livestock futures you can become a Premium Member. You can also follow us on YouTube for more examples of how to use the Fibonacci retracements with the ONE44 rules and guidelines. FULL RISK DISCLOSURE: Futures trading contains substantial risk and is not for every investor. An investor could potentially lose all or more than the initial investment. Commission Rule 4.41(b)(1)(I) hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under- or over-compensated for the impact, if any, of certain market factors, such as lack of liquidity. Simulated trading programs in general are also subject to the fact that they are designed with the benefit of hindsight. No representation is being made that any account will or is likely to achieve profits or losses similar to those shown. Past performance is not necessarily indicative of future results.
Bloomberg
21-05-2025
- Business
- Bloomberg
Bloomberg Daybreak: Europe 05/21/2025
Bloomberg Daybreak Europe is your essential morning viewing to stay ahead. Live from London, we set the agenda for your day, catching you up with overnight markets news from the US and Asia. And we'll tell you what matters for investors in Europe, giving you insight before trading begins. Today's Guests: Janet Mui, RBC Brewin Dolphin Head of Market Analysis (Source: Bloomberg)
